Results of the observational study EVA PLUS: Use of combined oral contraceptives with f olate in real clinical practice in Russia

DOI

https://dx.doi.org/10.18565/aig.2019.3.114-120

Khamoshina M.B.
Medical Institute, Peoples’ Friendship University of Russia, Moscow, Russia

Objective. To estimate the level of satisfaction with the use of the contraceptive Yaz® Plus by women and physicians in real clinical practice.
Subjects and methods. A prospective, multicenter observational study was conducted in 1484 women over 18 years of the age, who used Yaz® Plus for contraception.
Results. The use of the contraceptive Yaz® Plus was accompanied by a high satisfaction by both women (4.7 points out of 5) and physicians (4.8 points out of 5). Medication adherence during a year of therapy was 88.9%. The total observational time was 1406.69 women-years of medication use. The incidence of adverse events (AEs) was one event per 8.85 women-years of use. During the study, 159 AEs were recorded in 113 (7.61%) women. Most of the AEs were classified as mild (n = 131) and moderate (n = 28) AEs in 97 (6.54%) and 23 (1.55%) women, respectively.
Conclusion. The use of Yaz® Plus prescribed for contraception in real clinical practice was accompanied by a high level of satisfaction. The choice of physicians who have recommended Yaz® Plus determines the contraceptive effectiveness of the medication and the possibility of everyday compensation for the optimal daily dose of folates.

contraception

Yaz® Plus

satisfaction

tolerability

real clinical practice

Full text (in Russian)

Архипова М.П., Хамошина М.Б. Репродуктивное поведение: известные факты и новые гипотезы. Акушерство и гинекология: новости, мнения, обучения. 2018; 3: 15-20. [Arkhipova M.P., Khamoshina M.B. Reproductive behavior: known facts and new hypotheses // Obstetrics and Gynecology. News. Opinions. Learning. (in Russian)].
Committee on Health Care for Underserved Women. ACOG Committee Opinion No. 729: Importance of social determinants of health and cultural awareness in the delivery of reproductive health care. Obstet. Gynecol. 2018; 131(1): e43-8.
Радзинский В.Е., Хамошина М.Б., Маклецова С.А. Время понятной контрацепции. Оптимизация врачебного выбора гормональной контрацепции как путь сохранения здоровья женщин на популяционном уровне : информационный бюллетень. М.: Медиабюро Статус презенс; 2016. 24 с. [Radzinsky V.E., Khamoshina M.B., Makletsova S.A. Time to understand contraception. Optimization of the medical choice of hormonal contraception as a way to preserve the health of women at the population level: newsletter // StatusPraesens journal editors. Media Bureau Status of a business, 2016. 24 p. (in Russian)].
Радзинский В.Е., Аганезова Н.В., Дубровина С.О., Карахалис Л.Ю., Кулешов В.М., Мальцева Л.И., Межевитинова Е.А., Минкина Г.Н., Обоскалова Т.А., Подзолкова Н.М., Пустотина О.А., Спиридонова Н.В., Тарасова М.А., Тихомиров А.Л. Расширение доступа к гормональной контрацепции в России: прагматические решения. Резолюция совета экспертов. РМЖ. Мать и дитя. 2017; 25(26): 1946-9. [Radzinsky V. et al. Resolution Expert Board. Increasing access to hormonal contraception in Russia: pragmatic solutions //RMJ. Mother and child. 2017. No. 26. P. 1946-1949. (in Russian)].
Blode H., Klipping C., Richard F., Trummer D., Rohde B., Diefenbach K. Bioequivalence study of an oral contraceptive containing ethinylestradiol/drospirenone/levomefolate calcium relative to ethinylestradiol/drospirenone and to levomefolate calcium alone. Contraception. 2012; 85(2): 177-84.
Daly L.E., Kirke P.N., Molloy A., Weir D.G., Scott J.M. Folate levels and neural tube defects: implications for prevention. JAMA. 1995; 274(21): 1698-702.
Eichholzer M., Tönz O., Zimmermann R. Folic acid: a public-health challenge. Lancet. 2006; 367(9519): 1352-61.
Wald N.J., Law M.R., Morris J.K., Wald D.S. Quantifying the effect of folic acid. Lancet. 2001; 358(9298): 2069-73.
Schroecksnadel K., Frick B., Fiegl M., Winkler C., Denz H.A., Fuchs D. Hyperhomocysteinaemia and immune activation in patients with cancer. Clin. Chem. Lab. Med. 2007; 45(1): 47-53.
Peng Y., Dong B., Wang Z. Serum folate concentrations and all-cause , cardiovascular disease and cancer mortality : A cohort study based on 1999–2010 National Health and Nutrition Examination Survey (NHANES). Int. J. Cardiol. 2016; 219: 136-42.
Castaño P.M., Aydemir A., Sampson-Landers C., Lynen R. The folate status of reproductive-aged women in a randomised trial of a folate-fortified oral contraceptive: dietary and blood assessments. Public Health Nutr. 2014; 17(6): 1375-83.
Northrup H., Volcik K.A. Spina bifida and other neural tube defects. Curr. Probl. Pediatr. 2000; 30(10): 313-32.
Esfahani S.T., Cogger E.A., Caudill M.A. Heterogeneity in the prevalence of methylenetetrahydrofolate reductase gene polymorphisms in women of different ethnic groups. J. Am. Diet. Assoc. 2003; 103(2): 200-7.
Cordero A.M., Crider K.S., Rogers L.M., Cannon M.J., Berry R.J. Optimal serum and red blood cell folate concentrations in women of reproductive age for prevention of neural tube defects: World Health Organization guidelines. MMWR. Morb. Mortal. Wkly Rep. 2015; 64(15): 421-3.
http://grls.rosminzdrav.ru. Регистрационное удостоверение Джес Плюс. [Electronic resource] // https://grls.rosminzdrav.ru/. 2017. P. ЛП 001189-111111. URL: https://grls.rosminzdrav.ru/Grls_View_v2.aspx?routingGuid=c5dbd022-5166-4e73-930f-4b5bb82a70f5&t= (accessed: 11.03.2019).
Rivera R., Guerra A. Management of acne in women over 25 years of age. Actas Dermosifiliogr. 2009; 100(1): 33-7.
Hernádi L., Marr J., Trummer D., De Leo V., Petraglia F. Efficacy and safety of a low-dose combined oral contraceptive containing drospirenone 3 mg and ethinylestradiol 20 mcg in a 24/4-day regimen. Contraception. 2009; 80(1): 18-24.
Chaiyasit N., Taneepanichskul S. A study of cycle control, side effects and client’s satisfaction of a low dose combined contraceptive containing ethinylestradiol/drospirenone–N24/4 regimen. J. Med. Assoc. Thai. 2010; 93(5):517-22.
Bachmann G., Sulak P.J., Sampson-Landers C., Benda N., Marr J. Efficacy and safety of a low-dose 24-day combined oral contraceptive containing 20 μg ethinylestradiol and 3 mg drospirenone. Contraception. 2004;70(3): 191-8.
Bitzer J., Paoletti A.M. Added benefits and user satisfaction with a low-dose oral contraceptive containing drospirenone. Clin. Drug Investig. 2009; 29(2): 73-8.
Reynolds E. Vitamin B12, folic acid, and the nervous system. Lancet Neurol. 2006; 5(11): 949-60.

Received 15.03.2019

Accepted 20.03.2019

Khamoshina, Marina B., MD, professor, Department of Obstetrics and Gynecology, Medical Institute, Peoples’ Friendship University of Russia.
117198, Russia, Moscow, Miklukho-Maklaya str. 6.

For citation: Khamoshina M.B. Results of the observational study EVA PLUS: Use of combined oral contraceptives with f olate in real clinical practice in Russia. Akusherstvo i Ginekologiya/Obstetrics and Gynecology.2019; (3): 114-20. (in Russian)
https://dx.doi.org/10.18565/aig.2019.3.114-120

Results of the observational study EVA PLUS: Use of combined oral contraceptives with f olate in real clinical practice in Russia

Khamoshina M.B.

Keywords

References

About the Authors

Similar Articles